Liao YP, Jiang JL, Zou WY, Xu DR, Li J. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients. World J Gastroenterol 2015; 21(14): 4284-4292 [PMID: 25892880 DOI: 10.3748/wjg.v21.i14.4284]
Corresponding Author of This Article
Wai-Yi Zou, Associate Professor, Department of Hematology, the First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan 2nd Road, Yuexiu District, Guangzhou 510000, Guangdong Province, China. waiyizou@medmail.com.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Liao YP, Jiang JL, Zou WY, Xu DR, Li J. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients. World J Gastroenterol 2015; 21(14): 4284-4292 [PMID: 25892880 DOI: 10.3748/wjg.v21.i14.4284]
World J Gastroenterol. Apr 14, 2015; 21(14): 4284-4292 Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4284
Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients
Ya-Ping Liao, Jia-Lu Jiang, Wai-Yi Zou, Duo-Rong Xu, Juan Li
Ya-Ping Liao, Jia-Lu Jiang, Wai-Yi Zou, Duo-Rong Xu, Juan Li, Department of Hematology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510000, Guangdong Province, China
Author contributions: Zou WY and Li J designed the study and wrote the protocol; Zou WY and Liao YP designed the study and helped with all correspondence related to this paper; Zou WY and Liao YP instructed the whole study and manuscript writing; Liao YP, Jiang JL and Xu DR performed experimental studies; Liao YP and Jiang JL acquired the data; Liao YP managed the literature searches and analyses as well as the statistical analysis; Liao YP wrote the first draft of the manuscript; all the authors approved the final version of the manuscript.
Ethics approval: The study was reviewed and approved by Institutional Review Board of the First Affiliated Hospital, Sun Yat-sen University.
Informed consent: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest: No potential conflicts of interest relevant to this article were reported.
Data sharing: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Wai-Yi Zou, Associate Professor, Department of Hematology, the First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan 2nd Road, Yuexiu District, Guangzhou 510000, Guangdong Province, China. waiyizou@medmail.com.cn
Telephone: +86-20-28823388
Received: August 25, 2014 Peer-review started: August 26, 2014 First decision: September 27, 2014 Revised: November 19, 2014 Accepted: January 8, 2015 Article in press: January 8, 2015 Published online: April 14, 2015 Processing time: 232 Days and 20.8 Hours
Core Tip
Core tip: The threshold of pre-transplantation hepatitis B virus (HBV) DNA for allo-HSCT was defined as 103 IU/mL. Only 1 patient developed HBV reactivation due to early discontinuation of antiviral therapy. The hepatitis B surface antigen (HBsAg)(+), HBsAg(-)/hepatitis B core antibody(+) and non-HBV infected groups showed no statistically significant differences in the incidence of graft-vs-host disease, drug-induced liver injury, hepatic veno-occlusive disease death, survival times and post-transplantation cumulative survival rates. In summary, suppression of HBV DNA to < 103 IU/mL before transplantation, continued antiviral therapy and close monitoring of immune markers of hepatitis B and HBV DNA after transplantation may assure the safety of allogeneic hematopoietic stem cell transplantation.
